SCHEMBL4240248

SCHEMBL4240248

Brc1cnc2nc(-c3cccc(OCCc4ccccc4)c3)[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.49
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
AURKA O14965 2/20 0.46
HDAC6 Q9UBN7 8/20 0.45
HDAC3 O15379 7/20 0.44
HDAC4 P56524 7/20 0.44
HDAC1 Q13547 7/20 0.44
HDAC7 Q8WUI4 7/20 0.44
HDAC2 Q92769 7/20 0.44
HDAC10 Q969S8 7/20 0.44
HDAC11 Q96DB2 7/20 0.44
HDAC8 Q9BY41 7/20 0.44
HDAC9 Q9UKV0 7/20 0.44
HDAC5 Q9UQL6 7/20 0.44
PRMT5 O14744 4/20 0.42
MMP2 P08253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4235517 0.90 AURKA (0.46) AURKAHDAC6HDAC3HDAC4HDAC1
SCHEMBL4055350 0.85 SMN1; SMN2 (0.53) ESR1LMNAHTTSMN1; SMN2NPSR1
SCHEMBL4060144 0.84 SMN1; SMN2 (0.52) ESR1LMNAHTTSMN1; SMN2NPSR1
SCHEMBL4051984 0.84 SMN1; SMN2 (0.55) ESR1LMNAHTTSMN1; SMN2NPSR1
SCHEMBL4050654 0.84 AURKA (0.52) ESR1LMNAHTTSMN1; SMN2NPSR1
SCHEMBL4058201 0.83 SMN1; SMN2 (0.55) ESR1LMNAHTTSMN1; SMN2NPSR1
SCHEMBL13607836 0.83 HDAC6 (0.47) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL4057196 0.83 SMN1; SMN2 (0.50) LMNAHTTSMN1; SMN2NPSR1RXFP1
SCHEMBL4236251 0.83 SMN1; SMN2 (0.50) ESR1LMNAHTTSMN1; SMN2NPSR1
SCHEMBL4234520 0.83 SCD (0.46) AURKAHDAC6HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B ESR1 1649/4885LMNA 2175/4885HTT 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.